RecruitingNot ApplicableNCT06085781

A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

HN-BIO: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers


Sponsor

University Health Network, Toronto

Enrollment

60 participants

Start Date

Jan 29, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • Age \>/= 18 years
  • Histologically proven Head and Neck Squamous Cell carcinoma
  • Primary or nodal disease \> 3cm for biomarker imaging
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Planned for curative surgery or (chemo)radiotherapy
  • Willingness to undergo repeat MRI imaging
  • Able to receive and understand verbal and written information regarding study and able to give written informed consent
  • Adequate renal function: Calculated creatinine clearance \>/= 30ml/min
  • Be able to lie comfortably on back for 1 hour

Exclusion Criteria6

  • As judged by investigator evidence of systemic disease that makes unsuitable for study
  • Contra-indication for serial MRI scans
  • Previous solid tumor treated within last 5 years
  • Pregnancy
  • History of gadolinium contrast allergy
  • Non-reversible clotting abnormality

Interventions

OTHERfMRI

Functional Magnetic Resonance Imaging

OTHEROral Pimonidazole

200 mg and 300 mg tablets


Locations(1)

Princess Margaret Cancer Center

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06085781


Related Trials